Mursla Bio Introduces AI Precision Medicine Platform Built on Organ-Specific EV Isolation from Blood

• Platform is built on biologically labelled, organ-specific multi-omics data carried by extracellular vesicles isolated from 2ml plasma samples • Enables differentiated AI-powered biomarker discovery and IVD translation for patient stratification, therapeutic monitoring, surrogate markers and other diagnostic development programs • Publication of pre-print data, with support from Evotec International GmbH and University College London demonstrates validation of Platform’s capability for liver diseases

Qureight’s synthetic study arms validate clinical efficacy in pioneering rare lung disease treatment

Qureight, a deep-learning analytics company accelerating drug development through AI-powered data curation, today announced that its digitally-twinned synthetic control arm has been used in a breakthrough clinical trial application in place of a human placebo group, marking a world-first in lung disease research. The study, presented at the American Thoracic Society, demonstrates significant clinical efficacy for Avalyn’s inhaled pirfenidone (AP01), a promising treatment for idiopathic pulmonary fibrosis (IPF), a rare and high-mortality lung disease.

One2Treat, the leading company incorporating the patient voice into clinical development, launches One2Treat Voice app

One2Treat SA, a fast-growing tech company incorporating the patient voice in all strategic decisions about treatment assessments in Pharma R&D, today announced the launch of the One2Treat Voice app, a new module of their software platform.

Thermo Fisher Scientific introduces the next generation Thermo Scientific™ Vanquish™ Charged Aerosol Detector P Series for more sensitive detection of impurities

Bio-Rad Extends Anti-Idiotypic Antibody and SpyCatcher Reagent Ranges for Bioanalysis and Antibody Drug Development

MIB Agents' Community of Families Has Awarded $2.5M in Grants to Research Pediatric Bone Cancer

MIB Agents, a leading pediatric osteosarcoma nonprofit, announced it has awarded $2.5 million in research grants through its OutSmarting Osteosarcoma program, which is powered by families honoring children affected by the disease. At its upcoming FACTOR Conference (June 26–28) in Salt Lake City, the organization will award $700,000 in grants to 10 scientists advancing less toxic, more effective treatments. The grants, which include four $100,000 Hero Grants and six $50,000 Hope Young Investigator Grants, reflect a unique collaboration between researchers and the osteosarcoma community, with families actively funding and participating in the review of scientific proposals.

Symbiosis Expands Global Reach with Key Appointment of Angelika Rublack as Senior Business Development Manager

START Launches Hope Hub to Connect Patients, Physicians, and Advocacy Groups to Community-Based Cancer Trials

The new platform is designed to break down barriers to early-phase trial access, bringing "Hope Through Access" to communities and patients who need it most.

Insilico Medicine Completes Oversubscribed Series E, Bringing Total Funding to $123 Million

Insilico Medicine(“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced the close of its Series E financing round at a total of around $123 million, surpassing its initial target amid strong investor interest.

ClearNote Health Avantect® Pancreatic Cancer Test Enters Patient Enrollment Phase of Groundbreaking UK Study Targeting High-Risk Patients

ClearNote Health announced initiation of patient enrollment for a new study that aims to advance early detection of pancreatic cancer in individuals newly diagnosed with type 2 diabetes.

Astoriom Appoints Brittany Jackson as CFO

Key appointment to lead the company’s financial strategy and support continued global growth in sample stability and biorepository storage solutions

Microsoft Xbox Co-Founder, Cameron Ferroni, Joins PhenoTips as CTO

PhenoTips, a leading provider of precision medicine software, announces the appointment of Microsoft Xbox co-founder Cameron Ferroni as Fractional CTO to scale the Genomic Health Record platform and bolster leadership.

CN Bio introduces cross-species DILI services to enhance in vitro to in vivo extrapolation during preclinical drug development

Extends capabilities of industry-leading PhysioMimix DILI assay for comparative studies between animal species and human Generates deeper insights into inter-species differences to de-risk development pipelines and minimize animal testing

Echosens and Boehringer Ingelheim Expand Long-Standing Collaboration to Accelerate Progress in MASH Diagnosis and Care

Echosens and Boehringer Ingelheim have expanded their long-standing partnership to accelerate progress in MASH diagnosis and care.

Majority of Diagnostic Laboratory Leaders Bet Big on Digital Pathology and AI

Survey of 360 senior professionals finds modernization is key to overcoming longstanding industry challenges

Insilico Medicine Announces Nature Medicine Publication of Phase IIa Results Evaluating Rentosertib, the Novel TNIK Inhibitor for Idiopathic Pulmonary Fibrosis (IPF) Discovered and Designed with a Pioneering AI Approach

Phase IIa study results of Rentosertib were published simultaneously in Nature Medicine(IF = 58.7) and presented at the American Thoracic Society (ATS) 2025. Encouraging clinical data showed that patients receiving 60 mg QD Rentosertib experienced the greatest mean improvement in lung function, as measured by forced vital capacity (FVC), with a mean change of +98.4 mL, compared to a mean decline of -20.3 mL in the placebo group. Exploratory biomarkers analyses further validated the biological mechanism of TNIK, the novel target identified through a generative AI approach, supporting Rentosertib’s potential anti-fibrotic and anti-inflammatory effects. Artificial intelligence (AI) is rapidly transforming the pharmaceutical industry, reshaping the landscape from target identification to personalized medicine, and unlocking unprecedented opportunities to accelerate drug discovery and delivery. Despite growing adoption, only a few AI-discovered or AI-designed drug candidates have advanced to clinical trials, and even fewer have demonstrated clinical proof-of-concept.

TeleTracking and Palantir Partner to Transform Healthcare Operations with AI-Powered Insights

Inizio Evoke Announces Medical Leadership Evolution: Matthew Hoelzle Named Chief Medical Officer

Sionna Therapeutics Announces Positive Phase 1 Data for NBD1 Stabilizers SION-719 and SION-451 and Advances Both Programs in Clinical Development for Cystic Fibrosis

Sionna Therapeutics announces positive data from its Phase 1 clinical trials of SION-719 and SION-451, the company’s nucleotide-binding domain 1 (NBD1) stabilizers, in healthy volunteers, and the company’s next phase of clinical development.

Annual Cotiviti Client Conference Focuses on AI, Interoperability and Reducing Healthcare Costs